MIMEDX GROUP, INC.MDXG

時価総額

$10.7億

PER

胎盤由来アロガフト製品の有力企業。EPIFIXやAMNIOEFFECT、AXIOFILLなどの組織移植製品を展開。2023年末にEPIEFFECTを発売、2024年にHELIOGEN投入、同年TELA販売権を取得（初期対価500万ドル）。米国を中心に日本へ拡大。

概要財務

サマリーテーブルに戻る

	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income (loss) from continuing operations	-	-	-	-	-	-	-	-	-	-	-	67	42
Share-based compensation	1	2	6	11	17	18	15	12	15	15	13	17	17
Deferred income tax provision	-	-	-	-	-	-	-	-	-	-	-	38	-12
Shares received in settlement of litigation	-	-	-	-	-	-	-	-	-	-	-	-	9
Amortization of intangible assets	-	-	-	-	-	-	-	-	-	-	-	-	4
Depreciation	446,502	465,367	637,246	1	2	3	6	7	6	4	3	3	2
Loss on extinguishment of debt	-	-	-	-	-	-	-	-	-8	-	-	-	-1
Non-cash lease expenses	-	-	-	-	-	-	-	-	-	-	1	1	1
Credit loss expense	-	-	-	-	-	-	-	-	-	-	3	1	1
Other	-	-	-	-	-	-	-	-	-	-	-	-	1
Accounts receivable	1	6	8	11	27	11	-	11	3	5	6	12	3
Inventory	253,942	2	857,992	1	2	3	7	-7	1	1	2	8	2
Prepaid expenses	-	-	-	-	-	2	5	-0	-1	1	3	0	-1
Other assets	-	-96,657	-70,000	-	-	-	-	-	-	-	0	-2	1
Accounts payable	-	-81,112	1	1	3	-4	7	-6	0	-0	1	1	-1
Accrued compensation	-	-	-	-	-	-	-	-	-	-	-	2	3
Accrued expenses	-	3	352,881	1	2	6	16	-0	2	-21	2	-2	-1
Other liabilities	16,383	-12,731	-28,969	1	-1	1	1	-3	-2	-1	0	-0	-1
Net cash flows provided by (used in) operating activities of continuing operations	-	-	-	-	-	-	-	-	-	-	-	35	67
Net cash flows used in operating activities of discontinued operations	-	-	-	-	-	-	-	-	-	-	-	-8	-1
Net cash flows provided by (used in) operating activities	-6,664,771	-3,384,831	-285,477	17	19	26	36	-39	-30	-2	-18	27	66
Purchases of equipment	486,091	582,931	2	3	6	6	9	2	4	3	2	-	2
Cash paid for acquisitions	-	-	-	-	-	-	-	-	-	-	-	-	8
Other	-	-	-	-	-	-	-	-	-	-	-	-	0
Net cash flows used in investing activities	-702,508	-582,931	-3,025,414	-12	-1	-12	-9	1	-5	-3	-3	-2	-10
Proceeds from Long-Term Lines of Credit	-	-	-	-	-	-	-	-	-	-	-	-	30
Proceeds from Issuance of Secured Debt	-	-	-	-	-	-	-	-	-	-	-	-	20
Prepayment premium on Hayfin term loan	-	-	-	-	-	-	-	-	1	-	-	-	1
Deferred financing cost	-	-	-	-	1	0	-	7	3	-	-	-	1
Repayment of Hayfin term loan	-	-	-	-	-	-	-	-	-	-	-	-	50
Repayment of Citizens Revolving Credit Facility	-	-	-	-	-	-	-	-	-	-	-	-	30
Principal Payments of Secured Debt	-	-	-	-	-	-	-	-	-	-	-	-	-1
Proceeds from Stock Options Exercised	295,753	1	2	2	5	3	4	0	0	1	1	1	1
Stock repurchased for tax withholdings on vesting of restricted stock	-	-	-	-	-	1	5	1	2	5	1	-	3
Repurchase of Series B Preferred Shares	-	-	-	-	-	-	-	-	-	-	-	10	-
Other	-	-	-	-	-	-	-	-	-	-	-	-	-0
Net cash flows used in financing activities	10	7	41	-2	-36	-8	-9	63	62	-3	-1	-9	-34
Net change in cash	-	-	-	-	-	-	-	24	27	-9	-21	16	22